Hua Medicine Sustainability Profile
Hua Medicine, officially known as Hua Medicine (Shanghai) Co., Ltd., is a pioneering biopharmaceutical company headquartered in Shanghai, China. Founded in 2016, the company focuses on the development of innovative therapies for diabetes and related metabolic disorders, positioning itself at the forefront of the healthcare industry. With a commitment to advancing diabetes treatment, Hua Medicine has developed unique products, including its lead candidate, HM15136, which aims to improve glycaemic control. The company has achieved significant milestones, including successful clinical trials that underscore its potential to transform diabetes management. Recognised for its cutting-edge research and development capabilities, Hua Medicine is rapidly establishing itself as a key player in the global biopharmaceutical market, dedicated to enhancing patient outcomes through innovative solutions.
DitchCarbon Score
How does Hua Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hua Medicine's score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hua Medicine's reported carbon emissions
In 2023, Hua Medicine reported total carbon emissions of approximately 435,747,000 kg CO2e, comprising about 19,201,000 kg CO2e from Scope 1 and about 416,546,000 kg CO2e from Scope 2 emissions. This marks a significant increase from their 2022 global emissions, which were about 329,500,000 kg CO2e, with Scope 1 emissions at approximately 17,170,000 kg CO2e and Scope 2 emissions at about 312,330,000 kg CO2e. Hua Medicine has set ambitious reduction targets, aiming for a 30% reduction in both Scope 1 and Scope 2 emissions by 2030, starting from 2022. This commitment reflects their proactive approach to adopting low-carbon emission reduction technologies to mitigate future operational costs associated with high-emission activities. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Their emissions data is not cascaded from any parent organization, ensuring that the figures are specific to Hua Medicine (Shanghai) Ltd. Overall, Hua Medicine's climate commitments and reduction initiatives demonstrate a clear focus on sustainability and carbon footprint reduction within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 15,190 | 00,000,000 | 00,000,000 |
| Scope 2 | 413,090 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Hua Medicine's Industry?
How Carbon Intensive is Hua Medicine's Location?
Hua Medicine's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hua Medicine has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
